SIEBERT JOHN M

CIK 00011905583 companiesLENEXA, KS

SEC Profile

Transactions

Companies

Filings

CIK

0001190558

Recent Transactions

50 trades

Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Unit
2024-02-23−3,886→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2024-02-23+3,886→ 87,943 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2024-02-22+8,252→ 8,252 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2024-02-22+5,369→ 5,369 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2023-02-23+6,293→ 6,293 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2023-02-23+3,886→ 3,886 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2023-02-22+3,882→ 84,057 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2023-02-22−3,882→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2022-02-22+6,847→ 6,847 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2022-02-22+3,882→ 3,882 total
Disposition to Issuer
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2022-02-19−4,222→ 0 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2022-02-19+4,222→ 80,175 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2021-08-11−15,000→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2021-08-11$12.98/sh+15,000→ 75,953 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2021-02-19+7,365→ 7,365 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Restricted Stock Units
2021-02-19+4,222→ 4,222 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2020-02-21+9,305→ 9,305 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2020-02-21$23.99/sh+5,211→ 60,953 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2019-06-20−10,000→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2019-06-20$9.13/sh+10,000→ 55,742 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2019-04-25$9.13/sh+10,000→ 45,742 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2019-04-25−10,000→ 10,000 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2019-02-22+12,427→ 12,427 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2019-02-22+12,427→ 12,427 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2018-08-20$7.90/sh+8,722→ 28,285 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2018-08-20−7,457→ 0 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2018-08-20$9.24/sh+7,457→ 35,742 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2018-08-20−8,722→ 0 total
Award
ARADIGM CORP
Stock Option (Right to Buy)
2018-03-22+276,000→ 276,000 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2018-02-23+8,613→ 8,613 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2017-06-13+6,036→ 6,036 total
Award
ARADIGM CORP
Stock Option (Right to Buy)
2017-06-01+110,485→ 110,485 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2017-02-24+7,905→ 7,905 total
Award
ARADIGM CORP
Stock Option (Right to Buy)
2016-06-09+35,941→ 35,941 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2016-03-01+15,000→ 15,000 total
Award
ARADIGM CORP
Stock Option (Right to Buy)
2015-11-12+19,940→ 19,940 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2015-03-03+20,000→ 20,000 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2014-12-16$4.24/sh+2,188→ 19,563 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2014-12-16−2,188→ 2,187 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2014-01-21+7,457→ 7,457 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2013-12-12−2,187→ 4,375 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2013-12-12$4.24/sh+2,187→ 17,375 total
Award
ARADIGM CORP
Stock Option (Right to Buy)
2013-05-22+140,000→ 140,000 total
Award
ARADIGM CORP
Common Stock
2013-05-22$0.15/sh+100,000→ 501,697 total
Purchase
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2013-03-21$5.50/sh+3,000→ 15,188 total
Award
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Director Stock Option (Right to Buy)
2013-02-05+8,722→ 8,722 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2012-12-14$4.24/sh+2,188→ 12,188 total
Exercise/Conversion
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Stock Option (right to buy)
2012-12-14−2,188→ 6,562 total
Purchase
SUPERNUS PHARMACEUTICALS, INC.$SUPN
Common Stock
2012-12-04$8.14/sh+7,000→ 10,000 total
Award
ARADIGM CORP
Stock Option (right to buy)
2012-05-25+140,000→ 140,000 total

Companies

Recent Filings

Address

C/O CYDEX, INC. 10513 W. 84TH TERRACE

LENEXA, KS, 66214

View on SEC.gov